In conclusion, COPD is a global disease, with increasing prevalence and health-related impact. The loss of FEV 1 may be slowing down, but what is really needed is an intervention that improves it in ...

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...

Bronchiectasis is one of the most common highly heterogeneous chronic inflammatory airway diseases in China. It has a long course, heavy symptom burden, and is prone to recurrent acute exacerbations, ...